Medpace Holdings Inc. (NASDAQ: MEDP) experienced a significant after-hours surge of 15.69% following the release of its second-quarter financial results for fiscal year 2026.

The dramatic price movement was driven by the company reporting quarterly earnings and revenue that substantially exceeded analyst expectations. Medpace posted Q2 earnings per share of $4.25, beating the consensus estimate of $3.97 by 7.05%. Quarterly revenue reached $707.331 million, surpassing the estimated $687.647 million by 2.86%. Furthermore, the company demonstrated strong year-over-year growth, with GAAP net income rising 34.4% to $121.4 million and revenue climbing 17.2%.

Additional positive indicators included a 28.2% increase in net new business awards to $795.7 million and a 4.9% growth in backlog to $3.01 billion. The company also provided optimistic full-year guidance, forecasting revenue between $2.81 billion and $2.89 billion for 2026.